Adjuvant pazopanib does not PROTECT against recurrence of high risk initially localised renal cell cancer, but does provide novel insights
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Article
Change log
Authors
Stewart, GD
Leibovick, BC
Negrier, S
Figlin, RA
Abstract
Improved post-surgical management of the 70% of all renal cell cancer (RCC) patients who present to urological surgeons with initially localised RCC, to prevent subsequent progression, is an area of great need within uro-oncology.
Description
Keywords
Carcinoma, Renal Cell, Humans, Indazoles, Kidney Neoplasms, Neoplasm Recurrence, Local, Nephrectomy, Pyrimidines, Sulfonamides
Journal Title
Journal of Clinical Oncology
Conference Name
Journal ISSN
0732-183X
1527-7755
1527-7755
Volume Title
35
Publisher
American Society of Clinical Oncology
Publisher DOI
Sponsorship
GD Stewart has received educational grants from Pfizer and Intuitive Surgical; consultancy fees from Pfizer, EUSA Pharma and Cambridge Medical Robotics; Travel expenses from Pfizer and Speaker fees from Pfizer. RA Figlin has received research funding from Peloton, BMS, Argos Therapeutics, Exilexis, and Cerulean; consulting fees from Novartis, Pfizer, Nektar, Peloton, Calithera, and Acceleron. S Negrier reports honoraria from Pfizer, Novartis, EUSA Pharma, Ipsen Biotech and Bristol-Myers Squibb. BC Leibovich declares no conflicts of interest.